Clinical trials: Infections, Staphylococcal
Impetigo
Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.
- Trial name
- NCT00133848
- Testing
- SB-275833 ointment, 1%
- Where
- 22 sites in India, Italy and 3 more
- Volunteers
- 210 people
- Sponsor
- GlaxoSmithKline
Non-bullous Impetigo
A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo
The purpose of this study is to determine the efficacy of the topical antibiotic LTX-109 in terms of clinical and microbiological response in treatment of impetigo.
- Trial name
- NCT01803035
- Testing
- LTX-109 1 %, LTX-109 2 %
- Where
- 2 sites in Dominican Republic
- Volunteers
- 210 people
- Sponsor
- Lytix Biopharma AS
Orthopedic Disorders, Surgical Site Infection
Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial
Surgical site infections are a major postoperative complication and are mostly due to colonization with endogenous germs, like Staphylococcus aureus, Staphylococcus epidermidis or Propionibacterium acnes.
- Trial name
- DECO-SSI (NCT02560155)
- Testing
- Mupirocin 2% nasal ointement, Chlorhexidine sol 4%
- Where
- Switzerland
- Volunteers
- 1,300 people
- Sponsor
- Lindenhofgruppe AG
Staphylococcus Aureus, Surgical Wound Infection
Risk Factors for Staphylococcus Aureus Surgical Site Infections in Orthopedic and Trauma Surgery
The most commonly identified organism for Surgical Site Infection (SSI) in orthopedic surgery is Staphylococcus aureus but risk factors for mono microbial S.aureus SSI are not well-known.
- Conditions
- Staphylococcus Aureus, Surgical Wound Infection, Orthopedic Disorder, Traumatology
- Trial name
- ISO (NCT03040960)
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Grenoble
Staphylococcal Infections
Staphylococcus Aureus Carriers Students Nursing Oxacillin Resistant
The Staphylococcus aureus is an important pathogen bacteria actuating as an agent of a wide variety of infections, such as the superficials to the disseminates ones, its commonly find into hospitals ambient, assailing mainly…
- Trial name
- NCT00518076
- Where
- Brazil
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Impetigo
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
This is a Phase 2 study evaluating the safety, tolerability, systemic exposure, and activity of topical ATx201 GEL (2% and 4%) treatment for 1, 2, or 5 days in outpatients with primary nonbullous or bullous impetigo.
- Trial name
- NCT03429595
- Testing
- ATx201, ATx201 GEL Vehicle
- Where
- 16 sites in South Africa
- Volunteers
- 210 people
- Sponsor
- UNION therapeutics
Impetigo
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
This is multicenter, randomised, placebo controlled, parallel, blinded (double-blind for ozenoxacin versus placebo comparison and investigator blinded for retapamulin versus placebo comparison), superiority clinical study…
- Trial name
- NCT01397461
- Testing
- retapamulin 1% ointment, ozenoxacin 1% cream
- Where
- 19 sites in Germany, South Africa
- Volunteers
- 465 people
- Sponsor
- Ferrer Internacional S.A.
Staphylococcal Skin Infection, Abscess
Individualized vs. Household MRSA Decolonization
The purpose of this research study is to compare the effectiveness of commonly used decolonization treatments (application of mupirocin antibiotic ointment to the nose and bleach baths) when performed by individuals with a…
- Conditions
- Staphylococcal Skin Infection, Abscess, Furunculosis, Staphylococcus Aureus
- Trial name
- HOME2DS (NCT01814371)
- Testing
- 2% mupirocin ointment, Bleach Bath (dilute), Hygiene Protocol
- Where
- United States
- Volunteers
- 474 people
- Sponsor
- Washington University School of Medicine
Impacted Wisdom Tooth, Pain
Investigation of Effectiveness of Local Antibiotic With Platelet Rich Fibrin on Third Molar Surgery Outcomes In Vivo
The aim of this study was investigate the effectiveness of Local Antibiotic Applications With Platelet Rich Fibrin on Third Molar Surgery Outcomes In Vivo and In Vitro.
- Conditions
- Impacted Wisdom Tooth, Pain, Staphylococcus Aureus
- Trial name
- NCT05678296
- Testing
- Diagnosis, Analgesic, traditional osteotomies
- Where
- Cyprus
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ceren Melahat Donmezer
Staphylococcus Aureus
Network on Antimicrobial Resistance in Staphylococcus Aureus
Reduced susceptibility of Staphyloccus aureus to the glycopeptide antibiotic vancomycin is causing increasing concern worldwide in view of the threat of increased morbidity and mortality caused by such resistant organisms.
- Trial name
- NCT00341913
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Staphylococcal Infections
Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus
Patients admitted into the Intensive Care Unit (ICU) have an intravenous (IV) catheter (small plastic tube) placed in their vein.
- Trial name
- NCT00175370
- Testing
- Vancomycin
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University of British Columbia
Staphylococcus Aureus Pneumonias
Panton Valentine Leucocidin
Staphylococcus aureus expresses a variety of virulence factors, including Panton Valentine leukocidin (PVL), a cytotoxin. PVL is specifically associated with primary skin and soft-tissue infections and severe necrotizing…
- Trial name
- PVL (NCT02798497)
- Testing
- Serum and Blood samples
- Where
- France
- Volunteers
- 234 people
- Sponsor
- Hospices Civils de Lyon
Nosocomial Infections, Sepsis
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
The purpose of this study is to show whether Veronate, a donor-selected staphylococcal human immune globulin intravenous (IGIV), can prevent an infection in the blood caused by staphylococcal bacteria in premature babies weighing…
- Conditions
- Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia
- Trial name
- NCT00113191
- Testing
- Veronate
- Where
- 93 sites in United States, Canada
- Volunteers
- 2,000 people
- Sponsor
- Bristol-Myers Squibb
Cystic Fibrosis
Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis Patients
Staphylococcus aureus is not only one of the first pathogens infecting the airways of cystic fibrosis (CF) patients, but also a highly prevalent microorganism (>60% of all CF patients; European and American CF registries; (4,25)…
- Trial name
- StaphCI (NCT00669760)
- Testing
- non-interventional study
- Where
- 17 sites in Austria, Germany
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Prosthesis-related Infections, Staphylococcal Infections
Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty
The number of patients requiring joint replacement is increasing due to its success in restoring function and pain relief, and the growing population of the elderly.
- Trial name
- NCT00423982
- Testing
- Rifampin-combination therapy, Monotherapy
- Where
- 8 sites in Norway
- Volunteers
- 100 people
- Sponsor
- Oslo University Hospital
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
The purpose of this superiority study is to evaluate the efficacy and safety of exebacase in addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S.
- Trial name
- DISRUPT (NCT04160468)
- Testing
- Exebacase
- Where
- 55 sites in United States
- Volunteers
- 259 people
- Sponsor
- ContraFect
MRSA Infection
Two Strategies for Methicillin-resistant Staphylococcus Aureus (MRSA) Infection Prevention in Surgical Patients
The study is a two-arm controlled multi-centre trial of two strategies to reduce nosocomial MRSA transmission and infection among surgical patients. Enrolment and primary analyses will be performed at the hospital level.
- Trial name
- MOSAR-04 (NCT00685867)
- Testing
- Rapid molecular MRSA test, Hand hygiene promotion
- Where
- Switzerland
- Volunteers
- 126,750 people
- Sponsor
- University Hospital, Geneva
Staph Aureus Methicillin Resistant Colonization
Study of 2% Chlorhexidine Gluconate-Impregnated Bath Cloths to Prevent MRSA Colonization in Complex Continuing Care
The purpose of this study is to determine whether daily bathing with 2% chlorhexidine gluconate-impregnated antiseptic cleanser (CHG) significantly reduces incidence of colonization of hospitalized patients with…
- Trial name
- NCT01717690
- Testing
- CHG antiseptic body cleanser
- Where
- Canada
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Baycrest
Prosthetic Joint Infections of Hip, Staphylococcus Aureus Infection
Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection
This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage cocktail to treat and prevent the recurrence of a methicillin-susceptible Staphylococcus aureus prosthetic joint infection…
- Trial name
- PHAGE-2024-01 (NCT06456424)
- Testing
- Phage therapy
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Calgary
Impetigo, Secondarily Infected Traumatic Lesions
Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
An international, multi-centre, prospective three arm parallel-group, phase II proof of concept study comparing the efficacy and safety of two dosage regimens (BID 7 days and TID 7 days) of TD1414 2% cream and one dosage regimen…
- Trial name
- NCT00626795
- Testing
- TD1414 2% cream, Bactroban® (mupirocin) 2% cream
- Where
- 2 sites in United States, South Africa
- Volunteers
- 773 people
- Sponsor
- LEO Pharma